Cumberland Pharmaceuticals and Sandor Medicaids have signed a commercialization agreement for Caldolor (ibuprofen) injection in India.
According to the deal, Sandor will look after the Caldolor regulatory activities and further distribution and sales operations in the territory.
Cumberland will continue product formulation, development and manufacturing and will provide finished product to Sandor for sale.
Sandor Medicaids will make upfront and milestone payments, a transfer price and sales based royalties of Caldolor to Cumberland.
Sandor Medicaids managing director Rajeev Sindhi said, "We believe Caldolor can fill an unmet need in the hospital market in India, and look forward to communicating its benefits to the medical community here."
Injectable ibuprofen product Caldolor is indicated for the treatment of pain and fever, featuring analgesic, antipyretic and anti-inflammatory properties.
Cumberland chief executive officer A.J. Kazimi said, "Sandor has an established infrastructure to handle commercialization of hospital pharmaceutical products, and we look forward to working with them to make Caldolor available to a larger population of patients."
